Potent, selective CB1
cannabinoid receptor antagonist/inverse agonist (Ki
values are 12 and 4200 nM for CB1
receptors respectively). Increases locomotor activity following systemic administration in vivo
. Analog of SR141716A (Ki
= 14 nM).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold with the permission of the University of Connecticut
Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281.
Cosenza et al.
Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices.
Gifford et al.
Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo.
Gatley et al.
Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand.
Lan et al.
AAPS Pharmsci., 1999;1:E4
The citations listed below are publications that use Tocris products. Selected citations for AM 281 include:
Showing Results 1 - 10 of 24